CellGenix Completed First Step of Facility Expansion to Stay on Top of the Increasing Demands for GMP Cell Culture Reagents
Product News Jun 21, 2018
CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, successfully completed the first phase of its headquarters’ expansion as more customers approach late-stage clinical development and commercialization.
In a first step, the company added additional space to its headquarters in Freiburg, Germany. Quality control, research and development laboratories as well as logistics and warehouse space have already been put into operation.
As the next step, a state-of-the-art, automated filling and freeze-drying line will be implemented in the existing GMP facility increasing finished product capacity for recombinant proteins by more than tenfold. This second phase of expansion is expected to be completed in the spring of 2019.
Positive clinical data, a supportive financing climate and clearer regulatory requirements have led to a strong growth in the cell and gene therapy space. This is predicted to persist. The building extension allows CellGenix to continue meeting the increasing demands for GMP-grade raw materials as more and more promising cell and gene therapies approach market authorization and commercialization.
“We are really excited about our new facility and the additional flexibility it provides. It supports our goal to become a key provider in the fight against disease, the preferred supplier of raw materials and tools and trusted partner for large scale manufacturing in the cell, gene therapy and regenerative medicine space. The expansion of our facility is a result of the robust, sustainable and profitable growth we achieved over the last years,” says Prof. Dr. Felicia Rosenthal, CEO of CellGenix.
Frank Hecht, Vice President Marketing & Sales at CellGenix, adds: “With this expansion we strengthen our position as a leading partner for all companies active in the manufacturing of cell and gene therapies. It enables us to meet increasing demands for high quality raw materials and, ultimately, help more patients.”